361 related articles for article (PubMed ID: 27633593)
1. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
Iborra M; Beltrán B; Nos P
Gastrointest Endosc Clin N Am; 2016 Oct; 26(4):641-56. PubMed ID: 27633593
[TBL] [Abstract][Full Text] [Related]
2. [Fecal Calprotectin in Inflammatory Bowel Disease].
Lee J
Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
[TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
Burri E; Beglinger C
Swiss Med Wkly; 2012; 142():w13557. PubMed ID: 22481443
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.
Ikhtaire S; Shajib MS; Reinisch W; Khan WI
J Gastroenterol; 2016 May; 51(5):434-46. PubMed ID: 26897740
[TBL] [Abstract][Full Text] [Related]
6. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
Dolinšek J; Rižnik P; Sabath L; Mičetić-Turk D
Wien Klin Wochenschr; 2016 Apr; 128(7-8):253-9. PubMed ID: 26659704
[TBL] [Abstract][Full Text] [Related]
8. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Mendoza JL; Abreu MT
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
[TBL] [Abstract][Full Text] [Related]
9. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
10. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier E; Van Assche G
Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
[TBL] [Abstract][Full Text] [Related]
11. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
[TBL] [Abstract][Full Text] [Related]
12. [Faecal calprotectin is a useful biomarker for intestinal inflammation].
Theede K; Kiszka-Kanowitz M; Nordgaard-Lassen I; Nielsen AM
Ugeskr Laeger; 2014 Sep; 176(37):. PubMed ID: 25294035
[TBL] [Abstract][Full Text] [Related]
13. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
14. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
Langhorst J; Boone J
Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive testing in the management of children with suspected inflammatory bowel disease.
Dilillo D; Zuccotti GV; Galli E; Meneghin F; Dell'Era A; Penagini F; Colella G; Lewindon P; Carmagnola S; Farina E; Ardizzone S; Maconi G
Scand J Gastroenterol; 2019 May; 54(5):586-591. PubMed ID: 31032665
[No Abstract] [Full Text] [Related]
16. Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease.
Otoni CC; Heilmann RM; García-Sancho M; Sainz A; Ackermann MR; Suchodolski JS; Steiner JM; Jergens AE
J Vet Intern Med; 2018 May; 32(3):999-1008. PubMed ID: 29624721
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
18. [Role of biological markers in inflammatory bowel disease].
Gisbert JP; González-Lama Y; Maté J
Gastroenterol Hepatol; 2007 Mar; 30(3):117-29. PubMed ID: 17374324
[TBL] [Abstract][Full Text] [Related]
19. Use of biomarkers in inflammatory bowel disease.
Egea Valenzuela J; Antón Ródenas G; Sánchez Martínez A
Med Clin (Barc); 2019 Apr; 152(8):310-316. PubMed ID: 30502302
[TBL] [Abstract][Full Text] [Related]
20. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
